lunes, 30 de septiembre de 2019

Mylan pays $30M to settle charges of misleading investors on EpiPen rebates

Mylan pays $30M to settle charges of misleading investors on EpiPen rebates

The Readout

Damian Garde

More reads

  • White House weighs limits on U.S. portfolio flows into China. (Bloomberg)
  • Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates. (STAT)
  • Gene-test fraud billed $2.1 billion to U.S. Medicare program. (Bloomberg)

No hay comentarios:

Publicar un comentario